Alumis Inc

ALMSNASDAQ · USD
4.84USD0.00 (-5.84%)
1210

Alumis Inc (ALMS) Covered Calls

Alumis Inc trades in the Biotechnology industry with an IV Rank of 51.98%, average versus the past year. ALMS's highest covered call setup is the $8.00 strike expiring Apr 16, 2027, sorted by theoretical annualized return. It's 42.86% out of the money with 154 days to expiration, a 43.75% return until expiration, and a 103.69% theoretical annualized return. Across the setups shown, annualized returns run from 11.84% to 103.69% at strikes between $6.00 and $15.00, with 35 to 798 days to expiration, as of Nov 13, 2026.

Read more

Running ALMS covered calls helps you generate income from Alumis Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ALMS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ALMS stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ALMS covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ALMS covered call is worth writing.

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

2027-04-161548.0042.860.051.65245.0043.75103.69-0.89+0.43111.60
2026-12-18356.007.140.051.2045.008.0483.80-0.89+0.49361.15
2029-01-1979815.00167.860.204.80960.00171.4378.41-3.57+0.65184.60
2028-01-2143410.0078.570.254.90465.0083.0469.83-4.46+0.68124.65
2027-04-161547.0025.000.054.80145.0025.8961.37-0.89+0.691254.75
2027-01-15636.007.140.151.1555.009.8256.90-2.68+0.5081.00
2027-04-161546.007.140.501.7090.0016.0738.09-8.93+0.57221.20
2029-01-1979810.0078.570.054.50445.0079.4636.35-0.89+0.64684.45
2028-01-214347.0025.000.054.90145.0025.8921.78-0.89+0.701974.85
2029-01-197987.0025.000.054.90145.0025.8911.84-0.89+0.7014.85

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank51.98% Moderate
  • Market cap (M$)626
  • 52 weeks high-84.56%
  • 52 weeks low-3.20%
  • Analyst recommendationStrong Buy
    1.30
  • Target price$25.38
    424.38% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-12
  • P/E—
  • Future P/E—
  • EPS (ttm)-3.48
  • EPS growth next 5 years10.34%

As of Nov 17, 2026